D. farinae Dust Mite Allergy Shots: The American HDM SCIT Guide
Dermatophagoides farinae (American house dust mite) SCIT uses an FDA-standardized 10,000 AU/mL extract and produces the largest symptom-score effect in the allergen immunotherapy literature — SMD -1.669 per Kim 2021 JACI Practice network meta-analysis of 26 RCTs. Der f 1, Der f 2, and Der f 23 sensitize 70–100% of HDM-allergic patients; 85% cross-reactivity with D.
D. farinae (American House Dust Mite) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to d. farinae (american house dust mite) — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of d. farinae (american house dust mite) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of d. farinae (american house dust mite) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of d. farinae (american house dust mite) extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for d. farinae (american house dust mite) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing d. farinae (american house dust mite) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription d. farinae (american house dust mite) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat d. farinae (american house dust mite) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is D. farinae (American House Dust Mite)?
The biology, taxonomy, and clinical fingerprint of D. farinae (American House Dust Mite) — the foundation of how SCIT targets it.
Dermatophagoides farinae: the American house dust mite produces ~20 fecal pellets per day containing Der f 1 and Der f 2; a used mattress may harbor 100,000–10 million mites.
- Scientific name
- Dermatophagoides farinae
- Family
- PyroglyphidaeHouse dust mite family
- Type
- Indoor dust mite — perennial aeroallergen via fecal pellets in bedding, carpets, and upholstery
- Native to
- Continental and drier temperate indoor environments worldwide; dominant species in much of the central and western United States
- Allergen proteins
- Der f 1 (cysteine protease, 24–25 kDa, 70–100% IgE reactivity) — major allergen; shares ~80% identity with Der p 1 (major)Der f 2 (NPC2/MD-2 homolog, 14 kDa, 80–100% IgE reactivity) — major allergen; shares ~87–88% identity with Der p 2 (major)Der f 23 (peritrophin-like protein, 8 kDa) — major allergen; shares ~76% identity with Der p 23 (major)Der f 4 (alpha-amylase), Der f 7 (LPS-binding protein-like), Der f 8 (GST), Der f 10 (tropomyosin, 36–37 kDa — pan-allergen cross-reacting with shrimp and cockroach)Der f 43 — highest confirmed WHO/IUIS allergen number
- Particle size
- 10–40 μm (fecal pellets); >95% of mite allergen is fecal-pellet-associated
- Avoidance difficulty
- Nearly impossible
How D. farinae (American House Dust Mite) Allergy Presents
Symptoms by body system — useful for distinguishing D. farinae (American House Dust Mite) sensitivity from overlapping allergies and infections.
Respiratory
- Perennial allergic rhinitis: nasal congestion, sneezing, and postnasal drip year-round with seasonal peaks in autumn
- Asthma triggered by mite allergen — Sporik 1990 NEJM: all but one asthmatic child in the cohort had been exposed to >10 µg Der p 1/g at age 1
- Chronic sinusitis and nasal polyps in severe perennial HDM disease
- Upper respiratory symptoms that predictably worsen in autumn as mite populations peak following summer breeding
- Nocturnal symptoms are characteristic: mites concentrate in mattresses and pillows (100,000–10 million per mattress)
Ocular
- Allergic conjunctivitis with itching, tearing, and redness — year-round in HDM-sensitized patients
- Eye symptoms often worse in the morning after prolonged mattress exposure overnight
- Periorbital edema and dark circles from chronic rubbing (allergic shiners)
Dermal
- Atopic dermatitis flares in patients with Der f 11 (paramyosin) sensitization — Der f 11 is a major allergen in atopic dermatitis specifically
- Urticaria from direct mite exposure is uncommon but documented
- Eczema exacerbation with indoor humidity increases that drive mite proliferation
Systemic
- Fatigue and sleep disruption from nocturnal nasal symptoms and asthma
- Reduced quality of life and work/school performance from perennial uncontrolled symptoms
- Shellfish reactions in Der f 10 (tropomyosin)-sensitized patients — the pan-allergen bridge to shrimp, lobster, crab, and cockroach
The Kim 2021 network meta-analysis gave us something we didn't have before — a direct comparison showing dust mite SCIT has the largest symptom-score effect size across all immunotherapy modalities with an SMD of -1.669. For patients who have already optimized their bedroom environment and are still suffering year-round, this is one of the strongest treatment recommendations I can make in all of allergy.
Where D. farinae (American House Dust Mite) Triggers Year-Round
D. farinae (American House Dust Mite) is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundPerennial — peaks in autumn as mite populations surge after summer breeding at high humidity· Year-round with autumn peak; nocturnal symptoms are characteristic due to mattress/pillow concentration
US Exposure Map
23 high-intensity statesWhat D. farinae (American House Dust Mite) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
D. farinae shares ~85% IgE cross-reactivity with D. pteronyssinus via conserved Group 1 (cysteine protease) and Group 2 (NPC2/MD-2) allergens; Der f 10 (tropomyosin) creates the clinically important pan-allergen bridge to shellfish and cockroach.
Standard US dual-species vial covering D. farinae + D. pteronyssinus; maintenance targets 7–12 µg Der f 1 + 7–12 µg Der p 1
Der f 1 / Der p 1 share ~80% sequence identity; Der f 2 / Der p 2 share ~87–88%; Group 10 tropomyosin shares ~95%
Mite-Shellfish Cross-Reactivity via Tropomyosin
Der f 10 (tropomyosin, 36–37 kDa) shares 81% identity with shrimp Pen a 1 and ~80% with cockroach Bla g 7. HDM-sensitized individuals with Der f 10-specific IgE face elevated shellfish allergy risk — over 70% of HDM-allergic patients show IgE to shrimp in some studies. A positive Der f 10 IgE is the key biomarker.
Is SCIT Right for Your D. farinae (American House Dust Mite) Allergy?
Answer 5 questions to assess whether D. farinae allergy shots are right for your year-round dust mite symptoms.
How severe are your dust mite allergy symptoms?
The D. farinae (American House Dust Mite) SCIT Protocol
D. farinae SCIT uses FDA-standardized extract at 10,000 AU/mL; the AAAAI/ACAAI Practice Parameters recommend a maintenance dose of 7–12 µg Der f 1 per injection, reached over a 3–6 month weekly build-up.
Starting at maximum dilution (1:10,000), extract concentration is increased weekly toward the target maintenance dose of 7–12 µg Der f 1 per injection per AAAAI Practice Parameters. A 30-minute post-injection observation period is mandatory at every visit. Cluster protocols (4–8 week accelerated build-up) are available in selected patients with higher systemic reaction monitoring. Rush protocols achieve maintenance in days but carry elevated systemic reaction risk.
Monthly injections maintain immune tolerance at the target maintenance dose. The PAT study showed benefits persist 7 years after 3 years of SCIT. Most US allergists continue for at least 3–5 years; discontinuation is considered when the patient has been symptom-free for 3+ years on monthly injections.
Disease modification after 3–5 years of SCIT typically produces lasting benefit. Retrospective cohort data (N=118,754) show AIT reduced incident asthma risk by ~40% (RR 0.60). For patients with mast cell disorder or severe allergic disease, extended treatment duration should be discussed with your allergist.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for D. farinae (American House Dust Mite) SCIT
D. farinae SCIT is backed by the strongest immunotherapy evidence in the allergy literature — a 2021 network meta-analysis of 26 RCTs gives it the largest single-modality effect size across all aeroallergen immunotherapy options.
- SCIT symptom score SMD vs placebo (largest in IT literature)85%Kim JM et al. 2021, JACI Practice 9:4450 — network meta-analysis of 26 RCTs: SMD -1.669 (95% CI -2.7 to -0.639)
- ODACTRA TCRS reduction in North American Phase III trial17%ODACTRA Study P001, 1,482 subjects — 17% TCRS improvement vs placebo; pivotal FDA approval trial
- Risk reduction in moderate/severe asthma exacerbations (HDM SLIT-tablet asthma trial P014)33%Asthma trial P014, 834 European adults — 31–34% risk reduction in moderate/severe exacerbations
- ICS dose reduction in HDM-asthmatic children with impermeable mattress encasings73%Halken S et al. 2003, JACI — 73% vs 24% achieved ≥50% ICS dose reduction with encasings (P<0.01)
D. farinae SCIT produces the largest symptom-score effect size in the allergen immunotherapy literature (SMD -1.669, Kim 2021). Combined environmental control — humidity reduction to <50% (Arlian 2001: 10-fold mite reduction), impermeable mattress encasings (Halken 2003), and hot washing at ≥60°C — further amplifies immunotherapy outcomes. The 2024 WAO meta-analysis found multicomponent bedroom control achieved RR 3.39 for patient-reported improvement.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
D. farinae (American House Dust Mite) SCIT Side Effects
D. farinae SCIT side effects are among the best-characterized in allergy practice due to the FDA-standardized extract and extensive safety data from decades of clinical use.
Local reactions
4 documentedSystemic reactions
4 documentedNo deaths from SCIT in the US have been reported when standard protocols are followed. A baseline FEV1 ≥70% predicted is required before each injection, and patients with poorly controlled asthma should not receive SCIT on that day. Curex carries that safety record into at-home care: your first dose and every dose change are supervised live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand, and a board-certified allergist oversees gradual, week-by-week dose escalation.
SCIT vs Alternatives for D. farinae (American House Dust Mite)
D. farinae-sensitized patients have four well-characterized options: SCIT (strongest efficacy evidence), ODACTRA SLIT-tablet (FDA-approved at-home alternative), dust mite avoidance measures, and pharmacotherapy.
| Criterion | At-home SCIT (Curex)Best | ODACTRA SLIT-tablet | Avoidance measures | Medications |
|---|---|---|---|---|
| Effectiveness | Excellent — SMD -1.669, largest in IT literature (Kim 2021) | Good — 17% TCRS reduction; 31–34% asthma exacerbation reduction | Modest alone; significant when multicomponent (WAO 2024: RR 3.39 for bedroom control) | Good for symptom suppression; no disease modification |
| 5-yr cost | $3,500–$12,000 over 5 years | Moderate — no office visit costs; tablet cost varies | Low — $50–$300 one-time for encasings | $500–$2,000/yr ongoing indefinitely |
| Duration | 3–5 years weekly then monthly injections | 3–5 years daily sublingual tablet | Ongoing — must be maintained indefinitely | Indefinite daily use required |
| Convenience | At-home weekly self-injection with Curex; no clinic visits | Home-based daily after first in-office dose | Minimal lifestyle disruption | Daily pills and sprays |
| Safety | USP <797> serum; Zoom-supervised first/changed dose; epinephrine Rx on hand | Black-box warning; epinephrine Rx required | No treatment risks | Generally safe; long-term nasal steroid safety established |
| Lasting effect | Disease-modifying; 7+ years lasting benefit | Disease modification documented | Effective only while maintained | No lasting effect after stopping |
At-home SCIT (Curex)Best
ODACTRA SLIT-tablet
Avoidance measures
Medications
For patients with confirmed D. farinae sensitization and inadequate pharmacotherapy response, SCIT produces the highest degree of symptom control and the only truly disease-modifying outcome. Curex's at-home blood testing includes Der f 1, Der f 2, and Der f 23 component assays to identify specific molecular sensitization patterns before starting treatment. Curex now delivers that same subcutaneous immunotherapy as an at-home allergy shot at $129/month: a personalized Dermatophagoides serum compounded under USP <797>, with your first injection and every dose change supervised live over Zoom by the prescribing physician, a prescribed epinephrine auto-injector confirmed on hand, and week-by-week dose escalation — so eligible patients get the disease-modifying modality without weekly clinic visits.
What D. farinae (American House Dust Mite) SCIT Actually Costs
Most major US insurers cover D. farinae SCIT under standard allergy benefits when ordered by a board-certified allergist and supported by diagnostic testing; prior authorization may be required. Out-of-pocket cost depends on deductible and co-insurance. ODACTRA SLIT-tablet coverage varies by insurer; a prior authorization letter is typically required.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your d. farinae (american house dust mite) allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
D. farinae (American House Dust Mite) SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Most patients notice meaningful symptom reduction after completing the build-up phase — approximately 3–6 months of weekly injections. Some patients experience partial relief during build-up itself. The MERIT trial showed treatment effects were measurable at 14 weeks into treatment. Maximal benefit typically develops after 12–24 months of maintenance therapy. The Kim 2021 network meta-analysis, which is the largest systematic comparison, measured symptom-score effects across 26 double-blind placebo-controlled trials, confirming sustained benefit. Patients should expect to continue for at least 3 years before considering discontinuation; most allergists recommend 3–5 years of total treatment to maximize post-treatment durability.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.